Stem Cell Research for Type 1 Diabetes: Current Evidence and Future Directions

Stem cell research for type 1 diabetes has moved from laboratory models to first-in-human clinical trials, with several 2024 and 2025 studies reporting measurable insulin secretion and reduced insulin dependence in transplanted patients. For laboratory students, technicians, researchers, and diagnostic professionals, the practical question is no longer whether stem cell-derived islets can produce insulin in humans, but which manufacturing, quality control, and patient selection variables determine whether a given product is safe, consistent, and clinically meaningful. This article critically reviews the current evidence base, describes the laboratory workflows and quality checks that support clinical translation, and provides a framework for evaluating stem cell treatment claims.

At a Glance

The table below summarizes the main stem cell approaches currently in clinical testing for type 1 diabetes, the reported outcomes, and the key laboratory considerations for each.

The Clinical Problem and the Cell Supply Gap

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin for survival. While insulin therapy and closed-loop delivery systems improve glycemic control, they do not restore the physiologic regulation of glucose that intact beta cells provide. Human islet transplantation from deceased donors is an established treatment for insulin-requiring type 1 diabetes, but donor supply is far below demand, and the procedure requires lifelong immunosuppression. The stem cell therapies for diabetes review in Nature Medicine describes this supply problem as the central driver of research into stem cell-derived islet-like cells, which could provide a potentially limitless source of insulin-producing tissue.

The scientific rationale for stem cell approaches rests on the ability of human pluripotent stem cells to differentiate into pancreatic islet-like cells. This differentiation recapitulates key stages of pancreatic development, generating cells that express insulin, glucagon, and other islet hormones. The review of stem cell therapy in diabetes notes that researchers have investigated both mesenchymal stem cell infusion and transplantation of stem cell-derived beta cells and islet tissues over the past two decades. The two approaches differ fundamentally in their mechanism: MSCs are studied primarily for immunomodulation and possible preservation of residual beta cell mass, while stem cell-derived islets are intended to replace lost beta cell function entirely.

Core Scientific Principles of Stem Cell-Derived Islet Production

Pluripotent Stem Cell Sources and Differentiation

Human pluripotent stem cells used for islet differentiation come from two main sources: embryonic stem cells and induced pluripotent stem cells. Induced pluripotent stem cells can be generated from adult somatic cells through the expression of reprogramming factors, and chemically induced pluripotent stem cells represent a newer variant that uses chemical compounds instead of genetic factors. The 2024 case report of chemically induced pluripotent stem cell-derived islet transplantation demonstrated that autologous CiPSC islets could be transplanted beneath the abdominal anterior rectus sheath in a patient with type 1 diabetes, achieving insulin independence starting 75 days after transplantation.

Differentiation protocols typically guide cells through definitive endoderm, primitive gut tube, posterior foregut, pancreatic progenitor, and endocrine precursor stages before generating immature beta cells. The final product is often described as stem cell-derived islets or SC-islets, which contain multiple endocrine cell types. The patient-derived iPSC modeling review describes how these differentiation protocols have been applied to study monogenic beta cell disorders such as maturity-onset diabetes of the young and congenital hyperinsulinism, demonstrating that iPSC-derived islets can recapitulate disease-specific features including excess insulin secretion and increased beta cell proliferation.

Beta Cell Purity and Characterization

A persistent challenge in stem cell-derived islet production is contamination by off-target cells and polyhormonal cells that co-express multiple islet hormones. The CD133/CD49a purification study identified CD133 as a beta cell-enriched surface marker that, when combined with the pan-endocrine marker CD49a, significantly increased beta cell enrichment while reducing alpha cells, polyhormonal cells, and ductal cells. This sorting-based purification strategy worked across multiple pluripotent stem cell lines and differentiation protocols, providing a method for generating higher purity beta cell preparations for disease modeling and drug development.

For diagnostic laboratories, this purification work highlights the importance of flow cytometry and cell sorting as quality control tools. Laboratories evaluating stem cell-derived islet products should verify the proportion of single hormone-positive cells, the absence of polyhormonal cells, and the consistency of differentiation across batches. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides general principles for developing and validating the functional assays used to characterize cell products, including insulin secretion assays and viability measurements.

Functional Assessment of Stem Cell-Derived Islets

Functional characterization of stem cell-derived islets requires demonstration of glucose-responsive insulin secretion. In clinical trials, this is typically assessed through C-peptide measurements during mixed-meal tolerance tests. C-peptide is co-secreted with insulin and serves as a stable marker of endogenous insulin production. The zimislecel phase 1-2 study used detection of serum C-peptide during a 4-hour mixed-meal tolerance test to assess engraftment and islet function, with all 14 participants showing detectable C-peptide after infusion.

Laboratories supporting stem cell islet trials must validate their C-peptide assays according to established bioanalytical standards. The FDA Bioanalytical Method Validation Guidance describes the parameters that should be evaluated, including accuracy, precision, selectivity, sensitivity, reproducibility, and stability. For C-peptide assays used in clinical decision-making, the lower limit of quantitation is particularly important because patients with type 1 diabetes typically have undetectable or very low endogenous C-peptide at baseline.

Clinical Trial Evidence and Reported Outcomes

Chemically Induced Pluripotent Stem Cell-Derived Islets

The 2024 first-in-human case report described a patient who received autologous transplantation of chemically induced pluripotent stem cell-derived islets beneath the abdominal anterior rectus sheath. This was the preliminary analysis of a phase 1 clinical trial registered as ChiCTR2300072200. The patient achieved sustained insulin independence starting 75 days post-transplantation. Time-in-target glycemic range increased from a baseline of 43.18% to 96.21% by month 4, with glycated hemoglobin reaching a non-diabetic level. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.

This case is notable for several reasons. First, the use of autologous cells theoretically eliminates the need for immunosuppression, although the report does not describe the immunosuppression regimen in detail. Second, the abdominal anterior rectus sheath is an unusual transplant site compared to the portal vein or subcutaneous space. Third, the magnitude of the glycemic improvement, with time-in-range above 98% and HbA1c around 5% at 1 year, suggests robust graft function. The authors concluded that further clinical studies assessing CiPSC-islet transplantation in type 1 diabetes are warranted.

Allogeneic Stem Cell-Derived Islet Cells with Immunosuppression

The 2025 zimislecel study in the New England Journal of Medicine reported interim results from a phase 1-2 study of an allogeneic stem cell-derived islet-cell therapy. The study had three parts. In part A, participants received a half dose of 0.4 x 10^9 cells as a single infusion into the portal vein, with an option for a second half dose within 2 years. In parts B and C, participants received a full dose of 0.8 x 10^9 cells as a single infusion. All participants received glucocorticoid-free immunosuppressive therapy.

The primary end point in part A was safety. The primary end point in part C was freedom from severe hypoglycemic events during days 90 through 365, combined with a glycated hemoglobin level below 7% or a decrease of at least 1 percentage point from baseline at one or more time points between days 180 and 365. Secondary end points in part C included safety and insulin independence between days 180 and 365. A total of 14 participants, 2 in part A and 12 in parts B and C, completed at least 12 months of follow-up and were included in the analyses. C-peptide was undetectable at baseline in all 14 participants, and after infusion all participants had engraftment and islet function as evidenced by C-peptide detection. Neutropenia was the most common serious adverse event, occurring in 3 participants. The analyses were interim and not prespecified.

Genetically Edited Cells without Immunosuppression

The 2025 report of genetically modified allogeneic islet cells described transplantation of CRISPR-Cas12b edited donor islet cells into a man with long-standing type 1 diabetes. The cells were genetically edited to avoid rejection and transplanted into the participant's forearm muscle. He did not receive any immunosuppressive drugs. At 12 weeks after transplantation, he showed no immune response against the gene-edited cells, and C-peptide measurements showed stable and glucose-responsive insulin secretion. Four adverse events occurred, none of which were serious or related to the study drug. The trial was funded by the Leona M. and Harry B. Helmsley Charitable Trust and registered as EudraCT 2023-507988-19-00 and ClinicalTrials.gov NCT06239636.

This approach represents a different strategy from encapsulation or immunosuppression. Instead of protecting cells from the immune system or suppressing the immune system, the cells themselves are modified to evade immune recognition. The Harvard Medical Student Review article discusses how targeting human leukocyte antigen molecules using gene editing techniques such as CRISPR/Cas9 could increase graft tolerance, and how combining gene editing with encapsulation could support long-term cell survival.

Mesenchymal Stem Cell Transplantation

The 2022 randomized placebo-controlled trial of mesenchymal stem cell transplantation enrolled 21 newly diagnosed type 1 diabetes patients who received either autologous bone marrow-derived MSCs or placebo. Each patient in the experimental group received two doses of MSCs and was followed for at least 1 year. The results showed that the transplantation was safe and significantly reduced the number of hypoglycemic episodes. MSC transplantation improved HbA1c, shifted serum cytokine patterns from pro-inflammatory to anti-inflammatory, increased the number of regulatory T-cells in the peripheral blood, and improved quality of life. Early transplantation significantly improved HbA1c and C-peptide levels. The trial was registered at the Iranian Registry of Clinical Trials with identifier IRCT2016070428786N1.

MSC therapy differs from stem cell-derived islet transplantation in that MSCs are not intended to replace beta cells directly. Instead, their proposed mechanism involves immunomodulation, regeneration, and migration to damaged tissue upon systemic injection. This makes MSC therapy more analogous to disease-modifying immunotherapy than to cell replacement. The baricitinib trial in new-onset type 1 diabetes provides a useful comparison, showing that a JAK inhibitor preserved beta cell function as measured by C-peptide, with a median mixed-meal-stimulated mean C-peptide of 0.65 nmol/L per minute in the baricitinib group versus 0.43 nmol/L per minute in the placebo group at week 48.

Encapsulated Stem Cell-Derived Cells

Encapsulation devices physically separate transplanted cells from the host immune system while allowing diffusion of nutrients, oxygen, and insulin. The 2021 Cell Stem Cell study reported 1-year data from the first cohort of 15 patients who received subcutaneous implantation of pancreatic endoderm cells in non-immunoprotective macroencapsulation devices combined with an immunosuppressive regimen. Implants were well tolerated with no teratoma formation or severe graft-related adverse events. Patients had increased fasting C-peptide levels, increased glucose-responsive C-peptide levels, and developed mixed meal-stimulated C-peptide secretion. Explanted grafts contained cells with a mature beta cell phenotype that were immunoreactive for insulin, islet amyloid polypeptide, and MAFA.

The 2021 Cell Reports Medicine study provided additional data from 17 subjects aged 22 to 57 with type 1 diabetes who received PEC-01 cells implanted subcutaneously in VC-02 macroencapsulation devices. Engraftment and insulin expression were observed in 63% of VC-02 units explanted from subjects at 3 to 12 months post-implant. Six of 17 subjects demonstrated positive C-peptide as early as 6 months post-implant. Most reported adverse events were related to surgical implant or explant procedures or to side effects of immunosuppression.

The 2024 Nature Biotechnology study reported interim 1-year outcomes from a phase 1/2 multicenter trial (NCT03163511) that used higher cell doses in devices with an optimized membrane perforation pattern. Of 10 patients with undetectable baseline C-peptide, 3 achieved levels of at least 0.1 nmol/L from month 6 onward that correlated with improved continuous glucose monitoring measures and reduced insulin dosing. The patient with the highest C-peptide of 0.23 nmol/L increased time-in-range from 55% to 85% at month 12. However, beta cell mass in sentinel devices in this patient at month 6 was only 4% of the initial cell mass, indicating that substantial cell loss occurs after implantation and that improving efficacy will require addressing this loss.

Laboratory Workflow for Evaluating Stem Cell-Derived Islet Products

Receipt and Documentation

Laboratories receiving stem cell-derived islet products for quality assessment should follow a standardized intake procedure. This begins with verification of chain of custody documentation, including product identifier, lot number, cell count, viability, and storage conditions. The WHO Laboratory Quality Management System Handbook describes the essential elements of a quality management system, including document control, records, and internal audit, which apply directly to cell product testing laboratories.

Each product lot should have a unique identifier that links to all manufacturing records, release testing results, and clinical outcome data. This traceability is essential for investigating adverse events or product failures. The laboratory should maintain a log that records the date and time of receipt, the condition of the shipping container, the measured temperature if a temperature logger was included, and the identity of the person accepting the shipment.

Cell Identity and Purity Testing

Flow cytometry is the primary method for assessing cell identity and purity. Laboratories should establish panels that distinguish beta cells, alpha cells, and other endocrine cell types, as well as identify contaminating non-endocrine populations. The CD133/CD49a purification study provides a validated marker combination for enriching beta cells and reducing alpha cells, polyhormonal cells, and ductal cells.

For release testing, the laboratory should define acceptance criteria for the minimum proportion of single hormone-positive beta cells, the maximum allowable proportion of polyhormonal cells, and the maximum allowable proportion of off-target cell types. These criteria should be established before product release and should be based on the functional performance of reference lots. The laboratory should also assess cell viability using methods such as flow cytometry with viability dyes or metabolic assays.

Functional Assays

Glucose-stimulated insulin secretion assays are the standard functional test for stem cell-derived islets. The assay typically involves exposing cells to low and high glucose concentrations and measuring insulin or C-peptide in the supernatant. The Assay Guidance Manual provides guidance on developing and validating such assays, including considerations for assay format, controls, and data analysis.

For clinical trial samples, the mixed-meal tolerance test is the standard method for assessing graft function in vivo. The laboratory should have a validated protocol for C-peptide measurement that includes defined sampling times, a standardized meal stimulus, and appropriate quality controls. The FDA Bioanalytical Method Validation Guidance describes the validation parameters required for assays used to support clinical trials, including accuracy, precision, selectivity, sensitivity, reproducibility, and stability.

Sterility and Safety Testing

Cell products intended for human transplantation must meet sterility requirements. Testing should include aerobic and anaerobic bacterial culture, fungal culture, and mycoplasma detection. Endotoxin testing should be performed on the final product and on any reagents that contact the product. The WHO Laboratory Biosafety Manual provides guidance on biosafety practices for laboratories handling biological materials, including risk assessment, containment, and safe handling procedures.

For genetically modified cell products, additional testing is required to verify the intended genetic modification and to assess off-target effects. This includes sequencing to confirm the absence of unintended mutations at predicted off-target sites and functional assays to confirm that the modification achieves its intended effect, such as reduced expression of major histocompatibility complex molecules.

Quality Control and Assurance

Reference Standards and Controls

Every functional assay should include appropriate reference standards and controls. For insulin or C-peptide assays, this includes a standard curve spanning the expected range of patient samples, quality control samples at low, medium, and high concentrations, and a blank sample to assess background signal. The laboratory should participate in external quality assessment schemes where available to verify that results are comparable across laboratories.

For cell-based assays, the laboratory should maintain reference cell lines or reference cell preparations that can be used to monitor assay performance over time. Shifts in reference values may indicate changes in reagent lots, instrument performance, or operator technique. The WHO Laboratory Quality Management System Handbook describes the requirements for quality control, including the use of control materials, the establishment of acceptance criteria, and the documentation of corrective actions when controls fail.

Batch-to-Batch Consistency

Stem cell differentiation is a complex process with many potential sources of variability. These include the starting cell population, the quality and consistency of growth factors and other reagents, the timing of differentiation steps, and the culture conditions. The laboratory should monitor key process parameters and product characteristics across batches to identify trends that might predict product failure.

The cryopreservation review highlights an additional source of variability: the need for reliable cryopreservation methods to enable stable storage, distribution, and clinical administration of stem cell-derived aggregates. Current cryopreservation protocols result in low cell viability post-thaw and have challenges in scalability. The review discusses the fundamental physics of cryopreservation, including cryoprotective agents, CPA loading and unloading, cooling and rewarming rate selection, and why the cell aggregate microstructure of islets presents a particularly difficult challenge for cryopreservation.

Documentation and Record Keeping

Complete and accurate documentation is essential for cell product testing. The laboratory should maintain records of all testing performed, including the identity of the operator, the date and time of testing, the reagents and equipment used, the raw data, and the final results. Any deviations from the approved protocol should be documented and investigated.

The WHO Laboratory Quality Management System Handbook emphasizes that records should be legible, indelible, and stored in a manner that prevents loss or damage. Records should be retained for a period consistent with regulatory requirements and should be available for review by sponsors, regulators, and accrediting bodies.

Common Failure Patterns and Troubleshooting

Low Cell Viability Post-Thaw

One of the most common failures in stem cell-derived islet products is low viability after cryopreservation and thawing. The cryopreservation review notes that current protocols result in low cell viability post-thaw and have scalability challenges. The aggregate microstructure of islets makes them particularly difficult to cryopreserve because the three-dimensional structure creates variable cooling and warming rates across the aggregate, leading to ice crystal formation and cell damage.

Troubleshooting low post-thaw viability should begin with verification of the cryopreservation protocol, including the cryoprotective agent concentration, the cooling rate, and the storage temperature. The laboratory should also verify that the thawing procedure is performed consistently, including the temperature of the water bath, the duration of thawing, and the dilution and removal of the cryoprotective agent. Viability should be assessed both immediately after thawing and after a recovery period in culture, as some cells may recover function after an initial period of stress.

Insufficient Insulin Secretion

Products that show adequate viability but insufficient glucose-stimulated insulin secretion may have incomplete differentiation or maturation. The Nature Medicine review describes the scientific advances in deriving pancreatic islet-like cells from human pluripotent stem cells, but also notes that the differentiation process is complex and that the final product may not fully recapitulate the function of native islets.

The laboratory should assess the expression of key beta cell markers, including insulin, PDX1, NKX6.1, and MAFA, and should compare the glucose-stimulated insulin secretion response to reference preparations. If insulin secretion is low, the laboratory should evaluate whether the differentiation protocol was followed correctly, whether the starting cell population had the expected characteristics, and whether any reagents or growth factors were compromised.

Immune Rejection or Loss of Graft Function

Clinical trials have shown that graft function can decline over time, even when initial engraftment is successful. The Nature Biotechnology study found that beta cell mass in sentinel devices was only 4% of the initial cell mass at month 6 in the patient with the highest C-peptide, indicating substantial cell loss. The immune response modeling study used human immune system mice to examine graft infiltration and rejection, finding that allogeneic SC-islet grafts exhibited heavy immune infiltration, cell proliferation, and pro-fibrotic processes, whereas autologous grafts showed minimal infiltration and little fibrosis.

For laboratories monitoring graft function, a decline in C-peptide levels over time should trigger investigation. Possible causes include immune rejection, insufficient vascularization, cell death from hypoxia or nutrient deprivation, and loss of beta cell identity or function. The laboratory should work with the clinical team to determine whether additional testing, such as imaging of the graft site or biopsy, is warranted.

Records and Measurements

C-Peptide as the Primary Biomarker

C-peptide is the primary biomarker for assessing beta cell function in stem cell islet trials. It is co-secreted with insulin in equimolar amounts but has a longer half-life in circulation, making it a more stable marker of endogenous insulin production. The zimislecel study used detection of serum C-peptide during a 4-hour mixed-meal tolerance test to assess engraftment and islet function, with C-peptide undetectable at baseline in all participants.

Laboratories should establish reference ranges for C-peptide in the context of the mixed-meal tolerance test, including the expected peak time and the relationship between C-peptide levels and glycemic outcomes. The laboratory should also monitor C-peptide levels over time to assess graft durability, with a decline suggesting loss of beta cell mass or function.

Continuous Glucose Monitoring Metrics

Continuous glucose monitoring provides a more complete picture of glycemic control than single time point measurements. Key metrics include time-in-range, time above range, time below range, and glycemic variability. The CiPSC islet case report reported time-in-target glycemic range increasing from 43.18% at baseline to 96.21% by month 4, and the Nature Biotechnology study reported time-in-range increasing from 55% to 85% in the best responder.

Laboratories supporting clinical trials should ensure that continuous glucose monitoring data are collected, processed, and reported consistently. This includes standardization of the sensor placement, calibration, and data analysis methods. The laboratory should also establish criteria for classifying hypoglycemic events, as freedom from severe hypoglycemic events is a primary end point in some trials.

Glycated Hemoglobin

Glycated hemoglobin provides an integrated measure of average glucose levels over the preceding 2 to 3 months. The CiPSC islet case report reported glycated hemoglobin decreasing to a non-diabetic level, and the zimislecel study used glycated hemoglobin thresholds as part of the primary end point definition. The MSC trial reported that MSC transplantation improved HbA1c.

Laboratories performing HbA1c testing should use methods that are certified by the National Glycohemoglobin Standardization Program or an equivalent standardization program. The laboratory should participate in external quality assessment and should monitor the coefficient of variation of the assay to ensure consistent performance over time.

Safety and Regulatory Context

Biosafety Considerations for Cell Product Laboratories

Laboratories handling stem cell-derived islet products must follow appropriate biosafety practices. The WHO Laboratory Biosafety Manual provides guidance on risk assessment, containment levels, and safe handling procedures for biological materials. Cell products intended for human transplantation should be handled in a manner that prevents contamination and protects laboratory personnel.

The laboratory should conduct a risk assessment that considers the source of the cells, the potential for infectious agents, the procedures being performed, and the potential for aerosol generation. Standard precautions should be followed for all human-derived materials, and additional precautions may be required for genetically modified cells.

Regulatory Framework for Cell Therapy Products

Stem cell-derived islet products are regulated as biologic drugs or cell therapy products in most jurisdictions. The Nature Medicine review discusses the regulatory considerations that will need to be overcome for human stem cell-derived pancreatic islet-like cells to become the next cell therapy breakthrough for diabetes treatment. These considerations include manufacturing standards, product characterization requirements, preclinical testing, and clinical trial design.

The review of stem cell therapy in diabetes and the Biomolecules and Biomedicine review both note that large-scale clinical trials over the long term are necessary to verify early successes and assess the curative potential of stem cell therapy for type 1 diabetes. The npj Metabolic Health and Disease article emphasizes that a universal cure will require a larger beta cell mass and an immune privileged niche that could eliminate the need for systemic immunosuppression.

Professional Escalation Criteria

Laboratory professionals should escalate concerns when they observe results that fall outside established acceptance criteria or that suggest a potential safety issue. Specific escalation criteria include:

• C-peptide levels that decline significantly between consecutive measurements in a clinical trial participant
• Positive sterility test results in a product intended for transplantation
• Evidence of immune rejection, such as rising inflammatory markers or declining graft function
• Adverse events in clinical trial participants that may be related to the cell product
• Product characteristics that fall outside the release specifications, including viability, purity, or functional performance

When escalation occurs, the laboratory should document the finding, notify the appropriate personnel, and participate in the investigation. The WHO Laboratory Quality Management System Handbook describes the requirements for corrective and preventive action, including root cause analysis and verification of the effectiveness of corrective actions.

Limitations and Interpretation Challenges

Small Sample Sizes and Interim Analyses

Most of the clinical evidence for stem cell-derived islet transplantation comes from small studies with limited numbers of participants. The CiPSC islet case report describes results from a single patient. The zimislecel study included 14 participants who completed at least 12 months of follow-up, and the analyses were interim and not prespecified. The genetically edited cell report describes outcomes in a single participant.

These small studies can demonstrate feasibility and provide preliminary evidence of safety and efficacy, but they cannot establish the magnitude of the treatment effect or the frequency of rare adverse events. Laboratory professionals should interpret results from these studies with appropriate caution and should recognize that larger, longer-term trials are needed.

Heterogeneity of Products and Protocols

Stem cell-derived islet products differ across studies in terms of the starting cell source, the differentiation protocol, the final product composition, the delivery method, the transplant site, and the immunosuppression regimen. The encapsulated beta cell study used higher cell doses in devices with an optimized membrane perforation pattern, while the pancreatic endoderm cell study used a different device and cell product. These differences make it difficult to compare results across studies and to generalize findings from one product to another.

Laboratory professionals should be aware of the specific product characteristics and protocol details for each study they support. They should not assume that results from one product predict the performance of another product, even if both are described as stem cell-derived islets.

Unknowns in Immune Interactions

The immune response modeling study found that under the conditions tested, human SC-islet grafts were not rejected by an autologous immune system, even in the presence of autoreactive T cells. However, the study also identified limitations that remain to be addressed for a model of spontaneous autologous SC-islet infiltration and destruction. The study noted that SC-islet grafts had unique characteristics, including a high percentage of glucagon-positive cells and the presence of cysts and CD57-positive enterochromaffin cells, features not typically observed in endogenous or transplanted allogeneic primary pancreatic islets.

These findings highlight the uncertainty about how stem cell-derived islets interact with the immune system in humans. The presence of non-beta cell populations in the graft may have immunologic consequences that are not yet fully understood. Laboratory professionals should monitor immune parameters in clinical trial participants and should be alert to unexpected immune responses.

Frequently Asked Questions

What is the difference between mesenchymal stem cell therapy and stem cell-derived islet transplantation?

Mesenchymal stem cell therapy involves intravenous infusion of MSCs, which are proposed to work through immunomodulation, regeneration, and migration to damaged tissue. The randomized placebo-controlled MSC trial showed reduced hypoglycemic episodes, improved HbA1c, and increased regulatory T-cells in newly diagnosed type 1 diabetes patients. Stem cell-derived islet transplantation involves transplanting insulin-producing cells derived from pluripotent stem cells, with the goal of replacing lost beta cell function. The Nature Medicine review describes this approach as a potential solution to the islet supply problem.

How is graft function measured after stem cell-derived islet transplantation?

Graft function is primarily assessed through C-peptide measurements during mixed-meal tolerance tests. The zimislecel study used detection of serum C-peptide during a 4-hour mixed-meal tolerance test to assess engraftment and islet function. Additional measures include continuous glucose monitoring metrics such as time-in-range, glycated hemoglobin levels, and daily insulin dose requirements. The CiPSC islet case report reported time-in-target glycemic range, glycated hemoglobin, and insulin independence as outcome measures.

Do all stem cell-derived islet transplants require immunosuppression?

No. Some approaches use immunosuppression, while others aim to avoid it. The zimislecel study used glucocorticoid-free immunosuppressive therapy. The genetically edited cell report described transplantation of CRISPR-Cas12b edited cells without any immunosuppressive drugs. Encapsulation devices physically separate cells from the immune system, although the pancreatic endoderm cell study combined encapsulation with an immunosuppressive regimen. The npj Metabolic Health and Disease article discusses the goal of providing an immune privileged niche that could eliminate the need for systemic immunosuppression.

What are the main safety concerns with stem cell-derived islet transplantation?

Safety concerns include the risk of teratoma formation from residual undifferentiated cells, immune rejection, adverse events related to immunosuppression, and complications from the transplant procedure. The pancreatic endoderm cell study reported no teratoma formation or severe graft-related adverse events in 15 patients. The zimislecel study reported neutropenia as the most common serious adverse event, occurring in 3 of 14 participants. The encapsulated beta cell study found that beta cell mass in sentinel devices was only 4% of the initial cell mass at month 6, indicating substantial cell loss after implantation.

How is beta cell purity assessed in stem cell-derived islet products?

Beta cell purity is assessed using flow cytometry with markers that distinguish beta cells from other endocrine and non-endocrine cell types. The CD133/CD49a purification study identified CD133 as a beta cell-enriched surface marker that, when combined with CD49a, significantly increased beta cell enrichment while reducing alpha cells, polyhormonal cells, and ductal cells. Purity assessment should also include evaluation of the proportion of single hormone-positive cells and the absence of polyhormonal cells.

What is the current status of clinical trials for stem cell-derived islet transplantation?

Clinical trials are in early phases. The CiPSC islet case report described a first-in-human phase

Related Diagnostic Guides

• How to Calculate the Number of Cells in a Confluent Monolayer
• How to Store and Handle Growth Factors and Cytokines for Cell Culture
• DNA Extraction from Sperm Cells: Protocol for Forensic and Research Applications
• Luciferase Reporter Assay: Principles and Protocol for Gene Expression Studies
• Multiplex RT-qPCR for Simultaneous Detection of Canine Distemper Virus, Canine Parvovirus Type 2, and Canine Adenovirus Type 2 in Clinical Samples

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.. Cell, 2024.
• Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.. The New England journal of medicine, 2025.
• Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.. Stem cell research & therapy, 2022.
• Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.. The New England journal of medicine, 2025.
• Stem cell therapies for diabetes.. Nature medicine, 2025.
• Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.. The New England journal of medicine, 2023.
• Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes.. Cell stem cell, 2021.
• Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes.. Nature biotechnology, 2024.
• Rebuilding Beta-Cell Function: Advances In Replacement, Preservation And Regeneration.. 2026.
• Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders.. 2026.
• Modeling immune responses to autologous and allogeneic human stem cell-derived islet grafts in vivo.. 2026.
• What Is the Current State of Stem Cell Therapy in Diabetes?. 2026.
• Cryopreservation of stem cell-derived aggregates for type 1 diabetes cell therapy: Considerations and challenges.. 2026.
• CD133/CD49a discriminate between human pluripotent stem cell-derived pancreatic beta and alpha cells.. 2026.
• Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future. Biomolecules & biomedicine, 2025.
• The Role of Stem Cell Therapy in Treating Type 1 Diabetes and Scientific Advances in Evading an Immune Response. Harvard Medical Student Review, 2025.
• Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Medicine, 2021.
• Finishing the odyssey to a stem cell cure for type 1 diabetes. npj Metabolic Health and Disease, 2024.
• Stem Cell Educator therapy in type 1 diabetes: From the bench to clinical trials. Autoimmunity Reviews, 2022.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.